EverSource Wealth Advisors LLC Has $5.51 Million Stock Holdings in HealthEquity, Inc. $HQY

EverSource Wealth Advisors LLC raised its holdings in HealthEquity, Inc. (NASDAQ:HQY) by 21.2% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 65,890 shares of the company’s stock after purchasing an additional 11,545 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in HealthEquity were worth $5,506,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Sivia Capital Partners LLC acquired a new stake in shares of HealthEquity during the 2nd quarter worth about $306,000. Arrowstreet Capital Limited Partnership acquired a new position in HealthEquity in the 2nd quarter valued at about $4,747,000. Marshall Wace LLP bought a new position in HealthEquity in the 2nd quarter valued at about $5,483,000. Amundi raised its holdings in HealthEquity by 9.3% in the 2nd quarter. Amundi now owns 30,203 shares of the company’s stock valued at $3,059,000 after acquiring an additional 2,574 shares during the period. Finally, Jump Financial LLC acquired a new stake in HealthEquity during the second quarter worth approximately $449,000. 99.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity at HealthEquity

In other HealthEquity news, EVP Michael Henry Fiore sold 3,142 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $95.00, for a total value of $298,490.00. Following the sale, the executive vice president owned 59,113 shares in the company, valued at $5,615,735. This trade represents a 5.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gayle Furgurson Wellborn sold 2,439 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $90.00, for a total transaction of $219,510.00. Following the sale, the director directly owned 19,733 shares in the company, valued at approximately $1,775,970. The trade was a 11.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 17,905 shares of company stock valued at $1,651,280 in the last quarter. Insiders own 1.60% of the company’s stock.

HealthEquity Stock Performance

NASDAQ:HQY opened at $101.24 on Wednesday. HealthEquity, Inc. has a twelve month low of $72.76 and a twelve month high of $105.96. The company has a quick ratio of 3.44, a current ratio of 3.44 and a debt-to-equity ratio of 0.46. The stock’s 50-day simple moving average is $90.87 and its 200 day simple moving average is $84.93. The firm has a market capitalization of $8.46 billion, a PE ratio of 37.92, a price-to-earnings-growth ratio of 1.67 and a beta of 0.21.

HealthEquity (NASDAQ:HQY) last posted its earnings results on Thursday, May 28th. The company reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.13. HealthEquity had a net margin of 17.25% and a return on equity of 14.75%. The firm had revenue of $354.64 million during the quarter, compared to analysts’ expectations of $352.02 million. The business’s revenue for the quarter was up 7.2% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. On average, analysts anticipate that HealthEquity, Inc. will post 3.92 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Royal Bank Of Canada lifted their target price on HealthEquity from $100.00 to $108.00 and gave the stock an “outperform” rating in a report on Wednesday, June 3rd. Citizens Jmp increased their target price on HealthEquity from $110.00 to $111.00 and gave the stock a “market outperform” rating in a report on Monday, June 1st. KeyCorp reaffirmed an “overweight” rating on shares of HealthEquity in a research note on Tuesday, May 26th. Wells Fargo & Company set a $111.00 price objective on shares of HealthEquity in a research note on Monday, June 1st. Finally, Barrington Research reiterated an “outperform” rating and set a $110.00 price target on shares of HealthEquity in a research report on Friday, May 22nd. Eleven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $110.93.

About HealthEquity

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.